ArticleFrontiers in oncology2026
Spectral CT iodine quantification for peritoneal metastasis burden and resectability prediction in ovarian cancer: a retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Accurate preoperative assessment of peritoneal metastasis burden in ovarian cancer remains challenging as conventional CT lacks sensitivity for small-volume disease. Spectral CT iodine quantification provides objective metrics of tumor vascularity that may predict surgical resectability. This retrospective study evaluated iodine-based parameters for estimating surgical Peritoneal Cancer Index (PCI) and predicting complete cytoreduction (R0). Materials and methods: We retrospectively identified 145 ovarian cancer patients who underwent preoperative triphasic spectral CT scans and subsequent cytoreductive surgery between June 2022 and December 2023. Two blinded radiologists quantified iodine concentration (IC), normalized iodine concentration (NIC), spectral curve slope (λHU), and effective atomic number (Zeff). Patients were stratified by surgical PCI into low (≤6), intermediate (7-15), and high (≥16) burden subgroups. Statistical analyses included correlation studies, ROC curves, and multivariable logistic regression. Results: Iodine-based parameters demonstrated a strong correlation with intraoperative PCI (IC: r=0.85, NIC: r=0.74, both P<0.001). NIC increased progressively across tumor burden categories (0.43, 0.57, 0.71; P<0.001). For predicting R0 resection, NIC achieved optimal performance (AUC = 0.88, 95% CI: 0.81-0.94). The cutoff value ≤0.55 yielded sensitivity 84.5%, specificity 79.5%, and a negative predictive value of 94.8% for identifying patients who would achieve R0 resection (i.e., among patients with NIC ≤0.55, 94.8% achieved R0). A combined model (NIC + PCI + CA-125) achieved AUC = 0.93 (95% CI: 0.87-0.97) with excellent interobserver reproducibility (ICC >0.84). Conclusion: Spectral CT iodine quantification demonstrates potential as a complementary tool for estimating peritoneal metastasis burden and predicting surgical resectability. The NIC threshold of 0.55 shows promise for stratifying patients, though external validation is needed before integration into preoperative staging protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.